{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:14:27Z","timestamp":1780481667690,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ajog.2014.08.016","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T01:30:14Z","timestamp":1408325414000},"page":"188.e1-188.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas"],"prefix":"10.1016","volume":"212","author":[{"given":"Irina","family":"Usach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Blansit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee May","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2014.08.016_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1055-9965.EPI-08-0771","article-title":"Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004","volume":"18","author":"Goodman","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2014.08.016_bib2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2014.08.016_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2014.08.016_bib4","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e3181ef7b16","article-title":"Are all pelvic (nonuterine) serous carcinomas of tubal origin?","volume":"34","author":"Przybycin","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajog.2014.08.016_bib5","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2014.08.016_bib6","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdr536","article-title":"Survival in cancer of unknown primary site: population-based analysis by site and histology","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2014.08.016_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/DCR.0b013e31827901dd","article-title":"Anal versus rectal melanoma: does site of origin predict outcome?","volume":"56","author":"Bello","year":"2013","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ajog.2014.08.016_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","article-title":"The role of the fallopian tube in the origin of ovarian cancer","volume":"209","author":"Erickson","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2014.08.016_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ygyno.2007.09.027","article-title":"Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary","volume":"107","author":"Moore","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2014.08.016_bib10","unstructured":"National Institutes of Health. Sunitinib malate in treating patients with persistent or recurrent clear cell ovarian cancer. 2013. Available at: ClinicalTrials.gov. Accessed July 5, 2013."},{"key":"10.1016\/j.ajog.2014.08.016_bib11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cncr.24152","article-title":"CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study","volume":"115","author":"Tian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2014.08.016_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.28421","article-title":"Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group","volume":"120","author":"Brown","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2014.08.016_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00268-003-7019-3","article-title":"Gastrointestinal carcinoid tumors: factors that predict outcome","volume":"28","author":"Van Gompel","year":"2004","journal-title":"World J Surg"},{"issue":"Suppl 8","key":"10.1016\/j.ajog.2014.08.016_bib14","doi-asserted-by":"crossref","first-page":"viii5","DOI":"10.1093\/annonc\/mdr516","article-title":"Molecular approaches to personalizing management of ovarian cancer","volume":"22","author":"Bast","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2014.08.016_bib15","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e395","article-title":"Targeting the PI3K\/AKT\/mTOR pathway: biomarkers of success and tribulation","author":"Owonikoko","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ajog.2014.08.016_bib16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00280-013-2121-1","article-title":"PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types","volume":"71","author":"Britten","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ajog.2014.08.016_bib17","first-page":"1031","article-title":"BRCA2 in American families with four or more\u00a0cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2","volume":"60","author":"Schubert","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ajog.2014.08.016_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1999.5623","article-title":"Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations","volume":"76","author":"Zweemer","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2014.08.016_bib19","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1158\/1078-0432.CCR-12-3947","article-title":"Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions","volume":"19","author":"Chene","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2014.08.016_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/PGP.0b013e31826a629b","article-title":"Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas","volume":"32","author":"Horn","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajog.2014.08.016_bib21","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.humpath.2012.12.007","article-title":"Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?","volume":"44","author":"Gao","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajog.2014.08.016_bib22","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications","volume":"27","author":"Kurman","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajog.2014.08.016_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/his.12046","article-title":"Fallopian tube precursors of ovarian low- and high-grade serous neoplasms","volume":"62","author":"Vang","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.ajog.2014.08.016_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2014.08.016_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2014.08.016_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.4230","article-title":"Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling","volume":"231","author":"Bashashati","year":"2013","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ajog.2014.08.016_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1593\/neo.121228","article-title":"Interleukin-1beta promotes ovarian tumorigenesis through a p53\/NF-kappaB-mediated inflammatory response in stromal fibroblasts","volume":"15","author":"Schauer","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.ajog.2014.08.016_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.2000.5840","article-title":"Comparative study of ovarian cancer histopathology by registry pathologists and referral pathologists: a study by the Gilda Radner Familial Ovarian Cancer Registry","volume":"78","author":"Piver","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2014.08.016_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0002-9378(91)90628-5","article-title":"The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?","volume":"164","author":"Tyler","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2014.08.016_bib30","unstructured":"The North American Association of Central Cancer Registries. Springfield, IL: Registries of The North American Association of Central Cancer;\u00a02014."},{"key":"10.1016\/j.ajog.2014.08.016_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/00005650-200208001-00007","article-title":"Studying radiation therapy using SEER-Medicare-linked data","volume":"40","author":"Virnig","year":"2002","journal-title":"Med Care"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937814008473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937814008473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:54:15Z","timestamp":1774461255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937814008473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0002937814008473"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2014.08.016","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2014.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}